RHÖN-KLINIKUM AG | 08/08/2013

RHÖN-KLINIKUM AG witnesses pleasing Q2 growth

  • RHÖN-KLINIKUM AG reports growth of 7.1% growth in patient numbers versus H1 of previous year
  • Revenues increase by 8.4% to more than EUR 1.5 billion
  • Net consolidated profit for H1 of 2013 amounts to EUR 50.8 million (same period last year: EUR 50.3 million). EBITDA climbs by 4.1% to reach EUR 151.5 million.
  • Outlook for full year confirmed

Patient numbers and revenues at the Group of RHÖN-KLINIKUM AG witnessed further growth in the first half of 2013. In the first six months 1,346,258 patients were treated, 7.1% more than over the same period of the previous year. Revenues climbed by 8.4% to reach EUR 1.507 billion. The pleasing organic growth in revenues was further helped by the consolidation of Dr. Horst Schmidt Kliniken (HSK) in Wiesbaden.

EBITDA grew in the first three quarters of 2013 by 4.1% to EUR 151.5 million. EBIT increased over the same period by 5.6% to EUR 81.4 million. During the reporting period, net consolidated profit stood at EUR 50.8 million, and was thus 1.0% above the level of the same period in 2012.

After deducting non-controlling interests in profit of EUR 1.9 million from net consolidated profit, earnings per ordinary share stood at EUR 0.35 for the first six months. 

“As the figures of the first half of 2013 show, RHÖN-KLINIKUM AG is well on its way to achieving its traditionally strong results”, said Dr. Martin Siebert, chairman of the Board of Management of RHÖN-KLINIKUM AG. “The integration of Dr. Horst Schmidt Kliniken in Wiesbaden and the further development of our Gießen and Marburg University Hospital are proceeding in line with the goals set in terms of the timetable and action plan.”

At the beginning of June, the Board of Management gave the go-ahead for the comprehensive and Group-wide growth and transformation programme “ImPULS”. Under “ImPULS”, the primary objective is to gain market shares thanks to an even better care offering for our patients and within the framework of a quality offensive. “The rising earnings strength to be brought about under the “ImPULS” programme will enable us at the same time to make targeted investments over the next few years to shape up our sites for the future network-based care concepts both structurally and technologically“ adds Jens-Peter Neumann, the Group's CFO.

Against this background, the Company is expecting organic growth rates over the medium term to the tune of roughly 3.5% to 4.5% p.a. Building on “ImPULS”, it appears realistic, based on the current portfolio of facilities – i.e. without further acquisitions or structural measures –, to achieve an EBITDA margin of above 12% for the Group overall by 2015. On its path towards becoming an integrated health company, RHÖN-KLINIKUM AG, by extending the office terms of the two members of the Board of Management, Jens-Peter Neumann and Martin Menger, is moreover underscoring the importance of continuity.

For full-year 2013, the Company continues to expect revenues of EUR 3.03 billion which may fluctuate within a range of plus or minus 2.5%. Moreover, EBITDA is expected to reach EUR 325 million and net consolidated profit EUR 110 million. These figures may fluctuate within a range of plus or minus 5%.